SAR

SAREUM HOLDINGS PLC ORD 0.025P

TitleTime
Company Presentation at BioTrinityTue 28/04/20 | 07:00
Price Monitoring ExtensionMon 20/04/20 | 11:00
Second Price Monitoring ExtnFri 17/04/20 | 11:05
Price Monitoring ExtensionFri 17/04/20 | 11:00
Second Price Monitoring ExtnTue 14/04/20 | 11:06
Price Monitoring ExtensionTue 14/04/20 | 11:01
Global Licensing of FL3+Aurora ProgrammeThu 26/03/20 | 07:00
Half-year ReportThu 26/03/20 | 07:00
Publication: new SRA737 combinations in cancerThu 12/03/20 | 07:00
Result of AGMTue 17/12/19 | 13:36
AGM StatementTue 17/12/19 | 07:00
Notice of AGMWed 20/11/19 | 07:00
Sareum notes Sierra Oncology Q3 2019 resultsTue 05/11/19 | 10:56
Research Update - SDC-1802 anti-cancer posterWed 30/10/19 | 07:00
Research Update - AACR-NCI-EORTC abstractThu 17/10/19 | 07:00
Final ResultsTue 15/10/19 | 07:00
Notice of Full Year ResultsMon 07/10/19 | 07:00
Research Update - TYK2/JAK1 cancer programmeFri 27/09/19 | 07:00
Trading StatementTue 27/08/19 | 07:00
Change of AdviserFri 16/08/19 | 07:00
Sareum notes Sierra Q2 resultsThu 08/08/19 | 14:17
Additional disclosure concerning Michael OwenMon 29/07/19 | 16:29
Additional Funds RaisedFri 28/06/19 | 07:00
Sierra seeks strategic options for SRA737Thu 27/06/19 | 13:50
Successful FundraisingWed 26/06/19 | 07:00
PrimaryBid.com OfferTue 25/06/19 | 16:31
Placing to progress TYK2/JAK1 programmesTue 25/06/19 | 16:30
Portfolio UpdateThu 13/06/19 | 07:00
Key takeaways from SRA737 webcast at ASCOMon 03/06/19 | 16:00
Second Price Monitoring ExtnMon 03/06/19 | 11:05
Price Monitoring ExtensionMon 03/06/19 | 11:00
Positive SRA737 data presented at ASCOMon 03/06/19 | 07:00
ASCO abstracts for SRA737 publishedThu 16/05/19 | 07:00
Sareum notes Sierra Oncology Q1 2019 ResultsWed 08/05/19 | 12:41
SRA737 Phase I/IIa data to be presented at ASCOTue 23/04/19 | 07:00
Preclinical Data for SRA737 Presented at AACR 2019Tue 02/04/19 | 07:00
Sareum Holdings PLC Issue of OptionsTue 12/03/19 | 07:00
HALF-YEARLY RESULTS ENDED 31 DECEMBER 2018Mon 04/03/19 | 07:00
Sierra Oncology has reported its 2018 ResultsThu 28/02/19 | 14:04
New SRA737 preclin data to be presented at AACRThu 28/02/19 | 08:14
Results of AGMTue 18/12/18 | 12:35
AGM StatementTue 18/12/18 | 07:00
Amendment to Preclinical Efficacy AnnouncementFri 30/11/18 | 11:17
Preclinical Data for SRA737 in Ovarian CancerThu 15/11/18 | 10:24
AGM NOTICEWed 14/11/18 | 07:00
Directorate ChangeTue 13/11/18 | 07:00
Sierra Oncology Q3 2018 ResultsThu 08/11/18 | 12:28
Completion of PlacingFri 26/10/18 | 07:00
FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018Mon 01/10/18 | 07:00
Notice of ResultsThu 27/09/18 | 13:03
TYK2/JAK1 selected for certain cancersWed 26/09/18 | 07:00
Pre-Close Trading StatementTue 11/09/18 | 07:00
Selection of TYK2/JAK1 for autoimmune diseasesMon 10/09/18 | 07:00
Sareum notes Sierra Oncology Q2 2018 ResultsThu 09/08/18 | 13:15
Notification of PCA ShareholdingWed 11/07/18 | 09:38
AdvisersFri 15/06/18 | 07:00
Sareum regains rights to Aurora+FLT3 inhibitorsThu 31/05/18 | 07:00
SRA737 trial update in Sierra Oncology Q1 ResultsThu 10/05/18 | 12:21
AACR 2018 UpdateTue 17/04/18 | 12:45
Late-breaker abstract for SRA737 accepted for AACRThu 15/03/18 | 07:00
Interim ResultsTue 13/03/18 | 07:00
Sierra Oncology expands SRA737 development programTue 27/02/18 | 12:50
Notice of Interim ResultsTue 13/02/18 | 07:00
Issue of OptionsWed 20/12/17 | 11:00
Result of AGMThu 14/12/17 | 11:01
AGM StatementThu 14/12/17 | 07:00
Notice of AGM and Annual Report & AccountsMon 20/11/17 | 07:00
PlacingTue 14/11/17 | 12:05
Final ResultsThu 19/10/17 | 07:00
Sierra Oncology to host call on Chk1 inhibitorMon 18/09/17 | 12:00
Pre-Close Trading StatementTue 22/08/17 | 07:00